聯邦制藥(03933.HK):2021年全年純利9.88億元,同比增長40.6%
格隆匯3月24日丨聯邦制藥(03933.HK)公佈2021年全年業績,2021年實現收入人民幣97.034億元,同比增長10.6%;未計利息、税項、折舊及攤銷前溢利18.837億元,同比增長12.3%;公司擁有人應占本年度溢利9.881億元,同比增長40.6%;基本每股盈利53.70分;董事會建議派發年度的末期股息每股8分,以及特別股息每股2分。
公吿表示,在國家大力推動碳達峯、碳中和及生態文明建設的前提下,集團秉持“環保優先”的可持續發展理念,支持國家碳市場與清潔能源體系的建立,配合社會全面綠色轉型,致力形成環保循環經濟體系,打造國家級綠色工廠。同時,集團積極投身社會公益,於疫情防控、脱貧攻堅、助力教育等多項公共慈善事業取得突出成績,以實際行動回饋社會,履行企業的社會責任。根據全球指數編制公司MSCI(Morgan Stanley Capital International)發佈的最新評級報吿,集團ESG(Environmental, Social & Governance)評級為A級,並已連續兩年實現該項評級的提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.